Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Stock Price Down 3.3% – Here’s What Happened
by Michael Walen · The Markets DailyRecordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF – Get Free Report)’s stock price dropped 3.3% on Thursday . The stock traded as low as $58.00 and last traded at $58.00. Approximately 100 shares changed hands during trading, a decline of 36% from the average session volume of 157 shares. The stock had previously closed at $60.00.
Recordati Industria Chimica E Farmaceutica Stock Performance
The firm has a market capitalization of $11.97 billion, a P/E ratio of 21.94 and a beta of 0.25. The stock’s 50-day simple moving average is $57.74 and its two-hundred day simple moving average is $60.91. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 1.16.
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $1.08 EPS for the quarter. The firm had revenue of $834.86 million for the quarter. Recordati Industria Chimica E Farmaceutica had a net margin of 17.81% and a return on equity of 34.38%.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.
The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.
Featured Articles
- Five stocks we like better than Recordati Industria Chimica E Farmaceutica
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors